When a patient is deficient in IgA, they may have antibodies against IgA that can react with IgA present in donor plasma. During a transfusion these anti-IgA antibodies can bind to the IgA in the transfused product and trigger rapid mast cell and basophil degranulation, releasing mediators like histamine that lead to a sudden, life-threatening anaphylactic reaction. This is why anaphylaxis is the transfusion reaction most closely linked to IgA deficiency. Clinically, it presents during the transfusion with symptoms such as abrupt hypotension, bronchospasm or wheezing, flushing or urticaria, and sometimes angioedema, and requires immediate stopping of the transfusion and prompt treatment with epinephrine and supportive care. To reduce risk, use washed red blood cells or plasma from IgA-deficient donors when possible, or avoid IgA-containing products in known IgA-deficient patients. Other reactions—hemolytic, febrile, or transfusion-associated circulatory overload—have different mechanisms (such as ABO incompatibility, cytokine-mediated fever, or volume overload) and do not specifically hinge on IgA deficiency.

Hemovigilance is the systematic surveillance of transfusion-related adverse events, spanning from the donor through the transfusion to the patient. In the United States, hospitals work with the American Association of Blood Banks (AABB) and the Centers for Disease Control and Prevention (CDC) in a cooperative Hemovigilance program to report every transfusion adverse event. This program collects data on reactions (like fever, chills, anaphylaxis, TRALI, TACO), transfusion-transmitted infections, labeling or handling errors, and near-miss events, then analyzes the information to identify patterns and root causes. The goal is to prompt corrective actions—education, process changes, and policy updates—to prevent recurrence and improve overall transfusion safety. The other names don’t reflect this formal, national surveillance framework.

In IgA-deficient patients who have anti-IgA antibodies, transfusing donor IgA can trigger a severe anaphylactic reaction. The most effective way to prevent this is to minimize IgA exposure by removing donor plasma from the transfused product. Washed red blood cells have the plasma removed, leaving essentially IgA-free red cells for transfusion. In contrast, fresh frozen plasma, platelet concentrates, and cryoprecipitate all contain donor plasma and can introduce IgA, raising the risk of an anaphylactic reaction. Therefore, washing the red cells to remove plasma is the best preventive strategy.

Distinguishing TACO from TRALI hinges on whether the lung edema is driven by volume overload or by a capillary leak from an inflammatory reaction, and on signs of how the heart is handling the fluid. In transfusion-associated circulatory overload, the edema is cardiogenic. The heart can’t handle the rapid or large volume of transfused blood, so you see signs of fluid overload: hypertension, elevated jugular venous pressure, crackles on lung exam, possibly peripheral edema, and a congested heart pattern on imaging. BNP is often elevated because the heart is stressed. The situation improves with stopping the transfusion, giving loop diuretics, and slowing or avoiding further volume load. In contrast, transfusion-related acute lung injury is noncardiogenic edema from a donor-derived immune reaction that makes capillaries leaky. It presents with acute hypoxemia and bilateral infiltrates on imaging, but without signs of circulatory overload or volume overload, and heart function is typically normal. The management is supportive care and stopping the transfusion; diuretics don’t address the underlying capillary leak. That’s why the first statement captures the correct distinction: TACO shows cardiovascular overload with hypertension and signs of fluid overload, whereas TRALI shows noncardiogenic edema with hypoxemia and no volume overload. The other options don’t fit because they misstate the relationship between the conditions, their triggers, or their typical clinical features.